{
    "name": "olsalazine",
    "comment": "Rx",
    "other_names": [
        "Dipentum"
    ],
    "classes": [
        "5-Aminosalicylic Acid Derivatives"
    ],
    "source": "https://reference.medscape.com/drug/dipentum-olsalazine-342082",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not known whether drug distributed into breast milk, use caution",
            "5-ASA is excreted in breast milk & may cause diarrhea in infant",
            "However little is absorbed from oral olsalazine",
            "Avoid"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Patients with known or suspected hypersensitivity to salicylates, aminosalicylates or their metabolites, or excipients"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Mesalamine-induced acute intolerance syndrome may occur; drug is converted to mesalamine, which has been associated with acute intolerance syndrome that may be difficult to distinguish from exacerbation of ulcerative colitis; symptoms include cramping, acute abdominal pain and bloody diarrhea, sometimes fever, headache, and rash; monitor patients for worsening of symptoms while on treatment; discontinue therapy if acute intolerance syndrome suspected",
                "Some patients who have experienced a hypersensitivity reaction to sulfasalazine have similar reaction to drug or to other compounds that contain or are converted to mesalamine; mesalamine-induced hypersensitivity reactions may present as internal organ involvement, including myocarditis, pericarditis, nephritis, hepatitis, pneumonitis, and hematologic abnormalities; evaluate patients immediately if signs or symptoms of a hypersensitivity reaction present; discontinue therapy if an alternative etiology for signs and symptoms cannot be established",
                "There have been reports of hepatic failure in patients with pre-existing liver disease receiving therapy; because drug is converted to mesalamine, evaluate risks and benefits of therapy in patients with known liver impairment",
                "Patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema have reported more severe photosensitivity reactions when receiving therapy; advise patients to avoid sun exposure, wear protective clothing, and use a broad-spectrum sunscreen when outdoors",
                "Cases of nephrolithiasis have been reported with use of mesalamine; active moiety in drug, including stones with 100% mesalamine content; mesalamine-containing stones are radiotransparent and undetectable by standard radiography or computed tomography (CT); ensure adequate hydration during treatment",
                "Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) reported with use, discontinue therapy at first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation"
            ],
            "specific": [
                {
                    "type": "Renal toxicity",
                    "description": [
                        "Renal impairment, including minimal change disease, acute and chronic interstitial nephritis, and renal failure reported in patients given products that contain mesalamine or are converted to mesalamine; in animal studies, kidney was principal organ of mesalamine toxicity",
                        "Evaluate the risks and benefits of therapy in patients with known renal impairment or a history of renal disease or taking concomitant nephrotoxic drugs",
                        "Mesalamine is known to be substantially excreted by kidney, and risk of adverse reactions may be greater in patients with impaired renal function",
                        "Evaluate renal function in all patients prior to initiation and periodically while on therapy"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Diarrhea",
            "percent": "17"
        },
        {
            "name": "Abdominal pain",
            "percent": "11"
        },
        {
            "name": "Nausea",
            "percent": "6"
        },
        {
            "name": "vomiting",
            "percent": "5"
        },
        {
            "name": "Headache",
            "percent": "4"
        },
        {
            "name": "Arthralgia",
            "percent": "4"
        },
        {
            "name": "Dyspepsia",
            "percent": "4"
        },
        {
            "name": "Joint pain",
            "percent": "3.6"
        },
        {
            "name": "Rash",
            "percent": "1.8"
        },
        {
            "name": "itching",
            "percent": "1.5"
        },
        {
            "name": "Fatigue",
            "percent": "1.5"
        },
        {
            "name": "Bloating",
            "percent": "1.5"
        },
        {
            "name": "Depression",
            "percent": "1.3"
        },
        {
            "name": "Upper respiratory infection",
            "percent": "1"
        },
        {
            "name": "Anorexia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Interstitial lung disease",
            "percent": null
        },
        {
            "name": "pleurisy",
            "percent": null
        },
        {
            "name": "pleuritis",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Angioneurotic edema",
            "percent": null
        },
        {
            "name": "SJS",
            "percent": null
        },
        {
            "name": "TEN",
            "percent": null
        },
        {
            "name": "DRESS",
            "percent": null
        },
        {
            "name": "and AGEP",
            "percent": null
        },
        {
            "name": "n",
            "percent": null
        }
    ]
}